Screener
AbCellera Biologics Inc. ABCL Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:18 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001703057-26-000028
| Line item | Three months ended March 31, 2025 | Three months ended March 31, 2026 |
|---|---|---|
| Deferred revenue | 13,313 | (8,033) |
| Deferred grant income | (1,220) | (2,356) |
| Other assets | 7,320 | (1,741) |
| Net cash used in operating activities | (11,554) | (33,523) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (10,636) | (3,831) |
| Purchase of marketable securities | (164,990) | (166,308) |
| Proceeds from marketable securities | 190,027 | 143,802 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is AbCellera Biologics Inc.'s operating cash flow?
- AbCellera Biologics Inc. (ABCL) reported operating cash flow of -$33.52M in Q1 2026.
- How has AbCellera Biologics Inc.'s operating cash flow changed year-over-year?
- AbCellera Biologics Inc.'s operating cash flow decreased by 190.1% year-over-year, from -$11.55M to -$33.52M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about AbCellera Biologics Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude